Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.

BIO

$378.88

Updated: 24/09/2026, 11:38:59

Market Cap
$10.20B
Sector
Healthcare
Industry
Medical - Devices
Country
US
Stock valuation chart
One-year closing share-price history for BIO
Company Profile

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

USD
NYSE
CEO: Norman D. Schwartz
Employees: 7,450
https://www.bio-rad.com
Asset Summaries
Latest generated summaries for BIO

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for BIO.
Share price
$378.88
Market cap
$10.20B
Exchange
NYSE
Currency
USD
CEO
Norman D. Schwartz
Employees
7,450
IPO date
27/02/1980
Beta
1.07
Last dividend
$0.00
Day range
$374.77 – $382.91
52-week range
$236.73 – $396.23
1-day performance
-0.18%
1-year performance
60.05%
Current drawdown (1Y)
-4.38%
CIK
0000012208
CUSIP
090572207
ISIN
US0905722072
Created
07/12/2025, 03:00:01
Last update
24/09/2026, 11:38:59

Track Bio-Rad Laboratories, Inc. with an AI analyst

See which prediction-market events move BIO, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to BIO from your Railway `news_articles` table.

BIO-key Receives Notice of Non-Compliance from Nasdaq Related to Delay of its Form 10-Q Filing

GlobeNewsWire • STOCK • 10/06/2026, 19:00:00

BIO GREEN MED SOLUTION, INC. ANNOUNCES BUSINESS COMBINATION AGREEMENT TO ACQUIRE FUTURE NRG SDN.

GlobeNewsWire • STOCK • 04/06/2026, 18:10:00

Bio-Rad Laboratories, Inc. (BIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 03/06/2026, 14:41:59

Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program

TheNewswire • STOCK • 03/06/2026, 11:25:00

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

GlobeNewsWire • STOCK • 03/06/2026, 11:00:00

UPDATE: BIO-key Delivers Phishing-Resistant Biometric Security to Alabama's AOD Federal Credit Union

GlobeNewsWire • STOCK • 02/06/2026, 14:48:00

Wells Fargo Raises Bio-Rad Laboratories (NYSE: BIO) Price Target Amid Elliott Investment Management's Stake and Sartorius Holdings

Market Data • Market Data • 25/05/2026, 13:07:49

VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME

PRNewsWire • STOCK • 19/05/2026, 18:38:00

Elliott builds big stake in life-science tools supplier Bio-Rad Labs, WSJ reports

Reuters • STOCK • 17/05/2026, 23:38:19

Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad

WSJ • STOCK • 17/05/2026, 22:03:00

BIO-key Shares Expected to Temporarily Move to OTC™ Markets Tomorrow, Wednesday May 13th Following Nasdaq Suspension After Today's Market Close; BIO-key is Seeking to Restore Nasdaq Listing Expeditiously

GlobeNewsWire • STOCK • 12/05/2026, 18:01:00

Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript

Seeking Alpha • STOCK • 01/05/2026, 08:01:34